Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Abstract Background Blood-based biomarkers for Alzheimer’s disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta(1-42/1-40), glial fibrillary acidic pr...

Full description

Bibliographic Details
Main Authors: Inge M. W. Verberk, Elisabeth Thijssen, Jannet Koelewijn, Kimberley Mauroo, Jeroen Vanbrabant, Arno de Wilde, Marissa D. Zwan, Sander C. J. Verfaillie, Rik Ossenkoppele, Frederik Barkhof, Bart N. M. van Berckel, Philip Scheltens, Wiesje M. van der Flier, Erik Stoops, Hugo M. Vanderstichele, Charlotte E. Teunissen
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Alzheimer’s Research & Therapy
Subjects:
Blood-based biomarkers
Plasma GFAP
Plasma amyloid beta
Amyloid pathology
Alzheimer’s continuum
Online Access:http://link.springer.com/article/10.1186/s13195-020-00682-7

Internet

http://link.springer.com/article/10.1186/s13195-020-00682-7

Similar Items